| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Monday’s Close |
|---|---|---|---|---|---|
| AZN | Astrazeneca PLC | $37.56 | $95.16B | Downtrend |
Agios Rides on Tibsovo Approval Amid Reliance on Celgene
http://www.zacks.com/stock/news/329504/agios-rides-on-tibsovo-approval-amid-reliance-on-celgene?cid=CS-ZC-FT-329504
Oct 19, 2018 - Agios (AGIO) aims at commercializing its newly approved leukemia drug Tibsovo, which has great potential in the AML market. Heavy reliance on Celgene for royalties and collaboration revenues is a woe.
0
Top Analyst Reports for AstraZeneca, Salesforce & Mastercard
http://www.zacks.com/research-daily/187244/top-analyst-reports-for-astrazeneca-salesforce-mastercard?cid=CS-ZC-FT-187244
Oct 18, 2018 - Top Analyst Reports for AstraZeneca, Salesforce & Mastercard
0
Merck's Keytruda on a Roll in a Thriving Anti-PD-L1 Market
http://www.zacks.com/stock/news/328943/mercks-keytruda-on-a-roll-in-a-thriving-anti-pd-l1-market?cid=CS-ZC-FT-328943
Oct 18, 2018 - Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.
0
Stocks making the biggest move premarket: MS, GS, UNH, JNJ, WMT & more
https://www.cnbc.com/2018/10/16/stocks-making-the-biggest-move-premarket-ms-gs-unh-jnj-wmt--more.html
Oct 16, 2018 - Names on the move ahead of the open.
11
Healthcare 16-24% Target Net Gains Pace WallStars For October
https://seekingalpha.com/article/4211623-healthcare-16minus-24-percent-target-net-gains-pace-wallstars-october?source=feed_all_articles
Oct 15, 2018 - Big pharma drug makers and biotech continued to top the healthcare sector by broker targets. WallStars are distinguished by positive broker target price upsides.The Healthcare sector is comprised of 1
0
J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion
http://www.zacks.com/stock/news/327731/jj-jnj-gets-fda-approval-for-xarelto-label-expansion?cid=CS-ZC-FT-327731
Oct 12, 2018 - Johnson & Johnson's (JNJ) Xarelto gets FDA approval for reducing risk of major cardiovascular events in chronic coronary or peripheral artery disease patients.
0
Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts
http://www.zacks.com/stock/news/327579/merrimack-mack-focuses-on-early-stage-pipeline-and-cost-cuts?cid=CS-ZC-FT-327579
Oct 11, 2018 - Merrimack (MACK) focuses on the development of its two early-stage pipeline candidates, MM-121 and MM-310. The candidates have been progressing well and are imperative to the company's growth.
0
Altimmune Declines Too Much
https://seekingalpha.com/article/4210760-altimmune-declines-much?source=feed_sector_healthcare
Oct 09, 2018 - Altimmune, Inc. is a clinical stage immunotherapeutics company developing robust and durable immune responses intended for the prevention and treatment of several illnesses.The market is too pessimist
0
Top Research Reports for JPMorgan, American Express & FedEx
http://www.zacks.com/research-daily/185837/top-research-reports-for-jpmorgan-american-express-fedex?cid=CS-ZC-FT-185837
Oct 09, 2018 - Top Research Reports for JPMorgan, American Express & FedEx
0
Lexicon Likely Looking At Even More Competition In Type 1 Diabetes
https://seekingalpha.com/article/4210037-lexicon-likely-looking-even-competition-type-1-diabetes?source=feed_tag_editors_picks
Oct 05, 2018 - Data from Phase III trials of Lilly/Boehringer's Jardiance in Type 1 diabetes supports submission and commercialization, bringing another competitor into the market.Lexicon's sotagliflozin is not out
0
Page 1>
Related Companies
| Name | Exchange | Price | Mkt Cap | |
| GSK | GlaxoSmithKline PLC | NYSE | $39.21 | $97.25B |
| BMY | Bristol-Myers Squibb Company | NYSE | $61.3 | $100.03B |
| SNY | Sanofi | NYSE | $43.75 | $109.14B |
| LLY | Eli Lilly and Company | NYSE | $105.71 | $113.53B |
| NVO | Novo Nordisk A/S | NYSE | $47.64 | $114.84B |